BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
7 hedge funds and large institutions have $3.78M invested in BRAINSTORM CELL THERAPUTC in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.32M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$260K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$178K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.71K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$2.71K |
Top Sellers
BCLI Hedge Fund Activity: Q3 2014 in Review
7 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2014, worth a combined $3.78M.
Buyers outnumbered sellers: 7 funds opened new BCLI positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $3.32M.
- 7 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $3.78M of BRAINSTORM CELL THERAPUTC stock for Q3 2014.
- 7 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2014 and 0 closed out, a net change of +7 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2014 was Sabby Management, an estimated $3.32M added.
Based on aggregated 13F filings for Q3 2014.